Latest news with #TempusLoop
Yahoo
29-05-2025
- Business
- Yahoo
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.
Tempus AI is a leader in applying AI solutions to cancer diagnosis. The company announced a new platform for speeding up the discovery of new drug targets. Since it's still unprofitable, Tempus AI is an investment with a higher degree of risk. When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off to the horizon. It's understandable if you identify with this. After all, shares of Tempus AI, a healthcare-oriented artificial intelligence (AI) leader, have soared more than 54% year to date (as of this writing), while the S&P 500 has plunged over 5%. But there's no need to fret that you've missed the boat on Tempus AI stock. While its climb so far in 2025 is impressive, it's easy to see how this specialist in applying AI to the field of oncology can skyrocket even higher in the future. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Since its founding in 2015, Tempus AI has made great strides in advancing its AI solutions for the treatment of cancer. The company, in fact, characterizes itself as possessing what it "consider[s] to be one of the largest libraries of clinical and molecular oncology data in the world." It's with this resource that Tempus is able to provide physicians with a powerful diagnostic tool that helps to inform better treatment options. And the company continues to develop innovative solutions. Recently, Tempus announced a new tool to help identify new targets for cancer treatment: Tempus Loop. Using patient data, models, and CRISPR screening, Tempus Loop expedites the process of discovering and confirming potential drug targets -- something of incredible value considering what Chief Scientific Officer Kate Sasser recognizes as a "90% failure rate for preclinical assets to become real-world medicines."Essentially, Tempus Loop can be of great assistance to pharmaceutical companies as a way of reducing research and development spending. Already, Tempus has received attention from leading drugmakers. It recently announced an expanded partnership with AstraZeneca (NASDAQ: AZN) to discover new drug targets, among other things. While Tempus is at the forefront of the intersection between AI and oncology, this investment requires higher risk-tolerance at the moment since the business is still unprofitable. Before you buy stock in Tempus Ai, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tempus Ai wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $611,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $684,068!* Now, it's worth noting Stock Advisor's total average return is 889% — a market-crushing outperformance compared to 162% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 28, 2025 Scott Levine has no position in any of the stocks mentioned. The Motley Fool recommends AstraZeneca Plc. The Motley Fool has a disclosure policy. Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Journals
30-04-2025
- Business
- Business Journals
The Beat: Beacon prepares to launch next-gen disinfecting product
Welcome to Chicago Inno's The Beat, a twice-weekly look at the people, companies and ideas that are shaping Chicago's innovation economy. The Big One A Chicago startup born out of the pandemic is ready to move into more homes and businesses after spending a number of years in research and development. GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events Founded in 2020, Beacon Technology Solutions — winner of Inno Madness 2025, Chicago Inno's annual bracket-style head-to-head startup competition — makes a wall-mounted smart device that uses Far-UVC 222 nm light to disinfect a room. Beacon CEO Brian Clark said the Chicago startup has delivered its flagship product to hundreds of customers and will look to continue to expand its customer base in 2025. READ MORE: Inno Madness winner Beacon preparing to launch next-gen disinfecting product More from Chicago Inno Chicago VC firm Portal Innovations , which focuses on life-sciences innovation, announced an international expansion through a new partnership with Dublin City University that hopes to create new opportunities for biotech, medtech, quantum and AI startups across Ireland, the U.K. and Europe. , which focuses on life-sciences innovation, announced an international expansion through a new partnership with that hopes to create new opportunities for biotech, medtech, quantum and AI startups across Ireland, the U.K. and Europe. Chicago tech giant Tempus announced the launch of Tempus Loop this week, a new oncology-focused platform. Chicago boosts life-sciences growth While Chicago's life-sciences market is showing some signs of growth with developments such as Evanston Labs coming online, it still lags behind other major metros in key traits. In a Colliers report looking at local ecosystems' ability to support and sustain growth in the life-sciences industry, Chicago ranked ninth in the country, held back slightly by a lack of new developments. Boston received the top score in the second annual analysis of 18 markets, followed by the San Francisco Bay Area at No. 2 and San Diego in the third spot. READ MORE: How Chicago is building up life sciences — and where it still lags Sign up for the Business Journal's free daily newsletter to receive the latest business news impacting Chicago.
Business Wire
28-04-2025
- Business
- Business Wire
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-focused platform for target discovery and validation. Loop is Tempus' proprietary approach to novel target identification that integrates real-world patient data (RWD) with human-derived biological models and CRISPR-screens, all leveraging AI to rapidly uncover insights for pre-clinical therapeutic development. One of the biggest industry challenges has been translating promising preclinical experiments into treatments that can benefit patients. Conventional approaches in target discovery and validation rely on cell lines or animal models, which may not be reliable representations of human tumors. Loop's approach is uniquely powerful because it leverages Tempus' rich RWD to identify patient subpopulations with similar clinical, pathologic, and molecular patterns, followed by use of systems biological approaches to help reveal novel target genes and multimodal signatures. These signatures allow Tempus to seamlessly map patient subcohorts to relevant patient-derived organoids (PDOs), which the company has been expanding for years. By ensuring continuity between RWD and PDOs, Tempus can validate targets using high-throughput functional screens in models that more closely reflect patient attributes. This seamless integration—RWD to PDO and back—can help to enable rapid hypothesis generation and testing in the most relevant disease models, accelerating target discovery and validation. Tempus has already deployed its Loop platform to prioritize drug targets in patient subpopulations with severe unmet needs for a large pharmaceutical company. By incorporating a lab-in-the-loop strategy, its biological modeling and functional screening capabilities were able to confirm and validate these targets within a year, a significant acceleration of the standard discovery timeline. 'Novel target discovery continues to be a major challenge in oncology. Despite increased spending in R&D, we still have a 90% failure rate for preclinical assets to become real-world medicines,' said Kate Sasser, PhD, Chief Scientific Officer at Tempus. 'With Loop, we have integrated vast multimodal patient data, which includes outcome data, with more relevant human biological models and high-throughput functional screens, all wrapped with AI tooling, to ultimately help find new patient cohorts of interest and unique and clinically relevant targets. We've been very encouraged with this platform, speeding up the timelines for our drug discovery customers, while also increasing confidence in the clinical relevance of these targets.' For more information, visit here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of real-world data and biological modeling solutions in therapeutic research and discovery, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
